ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
04 10 2023
Historique:
received: 28 03 2023
accepted: 06 06 2023
medline: 9 10 2023
pubmed: 7 10 2023
entrez: 7 10 2023
Statut: ppublish

Résumé

Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that will ensure clinical and cost effectiveness. This European Respiratory Society (ERS) task force was formed to provide an expert consensus for the management of incidental findings which can be adapted and followed during implementation. A multi-European society collaborative group was convened. 23 topics were identified, primarily from an ERS statement on lung cancer screening, and a systematic review of the literature was conducted according to ERS standards. Initial review of abstracts was completed and full text was provided to members of the group for each topic. Sections were edited and the final document approved by all members and the ERS Science Council. Nine topics considered most important and frequent were reviewed as standalone topics (interstitial lung abnormalities, emphysema, bronchiectasis, consolidation, coronary calcification, aortic valve disease, mediastinal mass, mediastinal lymph nodes and thyroid abnormalities). Other topics considered of lower importance or infrequent were grouped into generic categories, suitable for general statements. This European collaborative group has produced an incidental findings statement that can be followed during lung cancer screening. It will ensure that an evidence-based approach is used for reporting and managing incidental findings, which will mean that harms are minimised and any programme is as cost-effective as possible.

Sections du résumé

BACKGROUND
Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that will ensure clinical and cost effectiveness. This European Respiratory Society (ERS) task force was formed to provide an expert consensus for the management of incidental findings which can be adapted and followed during implementation.
METHODS
A multi-European society collaborative group was convened. 23 topics were identified, primarily from an ERS statement on lung cancer screening, and a systematic review of the literature was conducted according to ERS standards. Initial review of abstracts was completed and full text was provided to members of the group for each topic. Sections were edited and the final document approved by all members and the ERS Science Council.
RESULTS
Nine topics considered most important and frequent were reviewed as standalone topics (interstitial lung abnormalities, emphysema, bronchiectasis, consolidation, coronary calcification, aortic valve disease, mediastinal mass, mediastinal lymph nodes and thyroid abnormalities). Other topics considered of lower importance or infrequent were grouped into generic categories, suitable for general statements.
CONCLUSIONS
This European collaborative group has produced an incidental findings statement that can be followed during lung cancer screening. It will ensure that an evidence-based approach is used for reporting and managing incidental findings, which will mean that harms are minimised and any programme is as cost-effective as possible.

Identifiants

pubmed: 37804174
pii: 7295842
doi: 10.1093/ejcts/ezad302
pii:
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Respiratory Society
ID : TF-2019-14

Informations de copyright

This article has been co-published with permission in the European Journal of Cardio-Thoracic Surgery and in European Respiratory Journal. © The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.

Auteurs

Emma L O'Dowd (EL)

Nottingham University Hospitals NHS Trust, Nottingham, UK.
University of Nottingham, Faculty of Medicine and Health Sciences, Nottingham, UK.

Ilona Tietzova (I)

Charles University, First Faculty of Medicine, Department of Tuberculosis and Respiratory Diseases, Prague, Czech Republic.

Emily Bartlett (E)

Royal Brompton and Harefield NHS Foundation Trust, Radiology, London, UK.

Anand Devaraj (A)

Royal Brompton and Harefield NHS Foundation Trust, Radiology, London, UK.

Jürgen Biederer (J)

University of Heidelberg, Diagnostic and Interventional Radiology, Heidelberg, Germany.
German Center for Lung Research DZL, Translational Lung Research Center TLRC, Heidelberg, Germany.
University of Latvia, Faculty of Medicine, Riga, Latvia.
Christian-Albrechts-Universität zu Kiel, Faculty of Medicine, Kiel, Germany.

Marco Brambilla (M)

Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Italy.

Alessandro Brunelli (A)

St. James's University Hospital, Department of Thoracic Surgery, Leeds, UK.

Joanna Chorostowska (J)

Institute of Tuberculosis and Lung Diseases, Warsaw, Genetics and Clinical Immunology, Warsaw, Poland.

Herbert Decaluwe (H)

University Hospitals Leuven, Thoracic Surgery, Leuven, Belgium.

Dirk Deruysscher (D)

Maastricht University Medical Centre, Department of Radiation Oncology (MAASTRO Clinic), GROW-School for Oncology and Developmental Biology, Limburg, The Netherlands.

Walter De Wever (W)

Universitaire Ziekenhuizen Leuven, Radiology, Leuven, Belgium.

Matthew Donoghue (M)

Galway Clinic Doughiska, Galway, Ireland.

Aurelie Fabre (A)

University College Dublin School of Medicine, Histopathology, Dublin, Ireland.

Mina Gaga (M)

Sotiria General Hospital of Chest Diseases of Athens, 7th Respiratory Medicine Department, Athens, Greece.

Wouter van Geffen (W)

Medical Centre Leeuwarden, Department of Respiratory Medicine, Leeuwarden, The Netherlands.
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands.

Georgia Hardavella (G)

Sotiria General Hospital of Chest Diseases of Athens, Respiratory Medicine, Athens, Greece.

Hans-Ulrich Kauczor (HU)

University of Heidelberg, Diagnostic and Interventional Radiology, Heidelberg, Germany.
German Center for Lung Research DZL, Translational Lung Research Center TLRC, Heidelberg, Germany.

Anna Kerpel-Fronius (A)

National Koranyi Institute of Pulmonology, Department of Radiology, Budapest, Hungary.

Jan van Meerbeeck (J)

UZ Antwerpen, MOCA, Edegem, Belgium.

Blin Nagavci (B)

Institute for Evidence in Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.

Ursula Nestle (U)

Kliniken Maria Hilf GmbH Monchengladbach, Nordrhein-Westfalen, Germany.

Nuria Novoa (N)

University Hospital of Salamanca, Thoracic Surgery, Salamanca, Spain.

Helmut Prosch (H)

Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Vienna, Austria.

Mathias Prokop (M)

Radboud University Nijmegen Medical Center, Department of Radiology, Nijmegen, The Netherlands.

Paul Martin Putora (PM)

Kantonsspital Sankt Gallen, Radiation Oncology, Sankt Gallen, Switzerland.
Inselspital Universitatsspital Bern, Radiation Oncology, Bern, Switzerland.

Janette Rawlinson (J)

European Lung Foundation, Tipton, UK.

Marie-Pierre Revel (MP)

Cochin Hospital, APHP, Radiology Department, Paris, France.
Université de Paris, Paris, France.

Annemiek Snoeckx (A)

University Hospital Antwerp, Radiology, Edegem, Belgium.

Giulia Veronesi (G)

Humanitas Research Hospital, Division of Thoracic and General Surgery, Rozzano, Italy.

Rozemarijn Vliegenthart (R)

UMCG, Groningen, The Netherlands.

Sabine Weckbach (S)

UniversitatsKlinikum Heidelberg, Heidelberg, Germany.
Bayer AG, Research and Development, Pharmaceuticals, Radiology, Berlin, Germany.

Torsten G Blum (TG)

HELIOS Klinikum Emil von Behring GmbH, Lungenklinik Heckeshorn, Berlin, Germany.

David R Baldwin (DR)

University of Nottingham, Faculty of Medicine and Health Sciences, Nottingham, UK.
Nottingham University Hospitals NHS Trust, Department of Respiratory Medicine, Nottingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH